Clinical and Research Interests
Dr. Fatemi is the Associate Chair for Neuroscience and Translational Research for the Department of Psychiatry; the Bernstein Endowed Chair in Adult Psychiatry; Professor of Psychiatry, Neuroscience and Pharmacology, at the University of Minnesota Medical School. Dr. Fatemi’s research interests include the molecular causes and the biological basis of neurodevelopmental disorders, primarily schizophrenia and autism. His clinical interests include treatment and psychopharmacology of major depression, bipolar disorder, and schizophrenia. He has over 15 years experience in the treatment of psychiatric disorders. Dr. Fatemi is a member of the American College of Psychiatrists, a Fellow the American College of Neuropsychopharmacology, and International College of Neuropsychopharmacology, and a Distinguished Fellow of the American Psychiatric Association.
Education and Training
- Residency in Psychiatry at University Hospitals, Cleveland, OH, 1992-1996
- Intern in Diagnostic Radiology at Univ of Cincinnati Hospital, OH, 1991-1992
- M.D. in Medicine, Case Western Reserve University, Cleveland, OH, 1991
- Ph.D. in Anatomy, University of Nebraska Medical Center-Omaha, NE, 1979
- M.S. in Anatomy, University of Nebraska Medical Center-Omaha, NE, 1978
- B.S. in Biology, Baylor University, Waco, TX, 1974
- Adult psychiatry, Diplomate of American Board of Psychiatry and Neurology
- Pain medicine, Diplomate of the American Board of Psych. and Neurology
- Psychosomatic medicine, Diplomate of American Board of Psych. and Neurology
(For a comprehensive list of recent publications, refer to PubMed, a service provided by the National Library of Medicine.)
Folsom TD, Thuras PD, Fatemi SH. Protein expression of targets of the FMRP regulon is altered in brains of subjects with schizophrenia and mood disorders. Schizophr Res. 2015 Jul;165(2-3):201-11.
Fatemi SH, Folsom TD. GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism. Schizophr Res. 2014 Nov 25;.
Fatemi SH, Folsom TD. Existence of monomer and dimer forms of mGluR5, under reducing conditions in studies of postmortem brain in various psychiatric disorders. Schizophr Res. 2014 Sep;158(1-3):270-1.
Fatemi SH, Reutiman TJ, Folsom TD, Rustan OG, Rooney RJ, Thuras PD. Downregulation of GABAA receptor protein subunits α6, β2, δ, ε, γ2, θ, and ρ2 in superior frontal cortex of subjects with autism. J Autism Dev Disord. 2014 Aug;44(8):1833-45.
Frye RE, Rossignol D, Casanova MF, Brown GL, Martin V, Edelson S, Coben R, Lewine J, Slattery JC, Lau C, Hardy P, Fatemi SH, Folsom TD, Macfabe D, Adams JB. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Front Public Health. 2013 Sep 13;1:31.
Rustan OG, Folsom TD, Yousefi MK, Fatemi SH. Phosphorylated fragile X mental retardation protein at serine 499, is reduced in cerebellar vermis and superior frontal cortex of subjects with autism: implications for fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling. Mol Autism. 2013 Nov 1;4(1):41.
Fatemi SH, Folsom TD, Rooney RJ, Thuras PD. Expression of GABAA α2-, β1- and ε-receptors are altered significantly in the lateral cerebellum of subjects with schizophrenia, major depression and bipolar disorder. Transl Psychiatry. 2013 Sep 10;3:e303.
Fatemi SH, Folsom TD, Kneeland RE, Yousefi MK, Liesch SB, Thuras PD. Impairment of fragile X mental retardation protein-metabotropic glutamate receptor 5 signaling and its downstream cognates ras-related C3 botulinum toxin substrate 1, amyloid beta A4 precursor protein, striatal-enriched protein tyrosine phosphatase, and homer 1, in autism: a postmortem study in cerebellar vermis and superior frontal cortex. Mol Autism. 2013 Jun 26;4(1):21.
Fatemi SH, Folsom TD, Rooney RJ, Thuras PD. mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway. Transl Psychiatry. 2013 Jun 18;3:e271.
Kneeland RE, Fatemi SH. Viral infection, inflammation and schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012 (In Press)
Folsom TD, Fatemi SH. The Involvement of Reelin in Neurodevelopmental Disorders. Neuropharmacology, 2012, (In Press).
Fatemi SH, Folsom TD, Reutiman TJ, Novak J, Engel R. Comparative gene expression study of the chronic exposure to clozapine and haloperidol in rat frontal cortex. Schizophrenia Research, 134:211-8, 2012.
Fatemi SH, Aldinger KA, Ashwood P, Bauman ML, Blaha CD, Blatt GJ, Chauhan A, Chauhan V, Dager SR, Dickson PE, Estes AM, Goldowitz D, Heck DH, Kemper TL, King BH, Martin LA, Millen KJ, Mittleman G, Mosconi MW, Persico AM, Sweeney JA, Webb SJ, Welsh JP. Consensus Paper: Pathological Role of the Cerebellum of Autism. Cerebellum, 11:777-807, 2012.
Fatemi SH, Folsom TD, Reutiman TJ, Novak J, Engel RH. Comparative gene expression study of the chronic exposure to clozapine and haloperidol in rat frontal cortex. Schizophr Res. 2011 Dec 9.
Fatemi SH, Folsom TD, Kneeland RE, Liesch SB. Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both Fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anat Rec (Hoboken). 2011 Oct;294(10):1635-45. doi: 10.1002/ar.21299.
Blatt GJ, Fatemi SH. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anatomical Record, 294:1646-1652, 2011.
Fatemi SH, Folsom TD. Dysregulation of fragile × mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study. Mol Autism. 2011 May 6;2:6.
Fatemi SH, Folsom TD. The role of fragile X mental retardation protein in major mental disorders. Neuropharmacology. 2011 Jun;60(7-8):1221-6.
Fatemi SH, Folsom TD, Thuras PD. Deficits in GABA(B) receptor system in schizophrenia and mood disorders: a postmortem study. Schizophr Res. 2011 May;128(1-3):37-43.
Fatemi SH, Folsom TD, Rooney RJ, Mori S, Kornfield TE, Reutiman TJ, Kneeland RE, Liesch SB, Hua K, Hsu J, Patel DH. The viral theory of schizophrenia revisited: Abnormal placental gene expression and structural changes with lack of evidence for H1N1 viral presence in placentae of infected mice or brains of exposed offspring. Neuropharmacology. 2011 Jan 26.
Karkhane-Yousefi M, Folsom TD, Fatemi SH. A review of vareniclines’s efficacy and tolerability in smoking cessation studies in subjects with schizophrenia. Journal of Addiction Research and Therapy, S4:3045, 2011.
Fatemi SH. Invited commentary: Reelin as a stress resilience factor in depression & psychosis. Neuropsychopharmacology, 36: 2371-2372, 2011.
Fatemi SH, Folsom TD, Reutiman TJ, Braun NN, Lavergne LG. Levels of phosphodiesterase 4A and 4B are altered by chronic treatment with psychotropic medications in rat frontal cortex. Synapse. 2010 Jul;64(7):550-5.
Fatemi SH, Reutiman TJ, Folsom TD, Rooney RJ, Patel DH, Thuras PD. mRNA and protein levels for GABAAalpha4, alpha5, beta1 and GABABR1 receptors are altered in brains from subjects with autism. J Autism Dev Disord. 2010 Jun;40(6):743-50.
Fatemi SH, Reutiman TJ, Folsom TD. The role of lithium in modulation of brain genes: relevance for aetiology and treatment of bipolar disorder. Biochem Soc Trans. 2009 Oct;37(Pt 5):1090-5.
Fatemi SH, Folsom TD, Reutiman TJ, Huang H, Oishi K, Mori S. Prenatal viral infection of mice at E16 causes changes in gene expression in hippocampi of the offspring. Eur Neuropsychopharmacol. 2009 Sep;19(9):648-53.
Fatemi SH. Potential microbial origins of schizophrenia and their treatments. Drugs Today (Barc). 2009 Apr;45(4):305-18.
Fatemi SH, Folsom TD, Reutiman TJ, Abu-Odeh D, Mori S, Huang H, Oishi K. Abnormal expression of myelination genes and alterations in white matter fractional anisotropy following prenatal viral influenza infection at E16 in mice. Schizophr Res. 2009 Jul;112(1-3):46-53. Epub 2009 May 31.
Fatemi SH, Reutiman TJ, Folsom TD. Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats. Schizophr Res. 2009 Jun;111(1-3):138-52.